OrbiMed Advisors — Portfolio, Funds & Investments

At a glance

OrbiMed Advisors appears in 2 funding rounds tracked by ValueAddVC since 2025, leading 1. Its most recent tracked deal was Biobeat's $50M Series B round (Dec 30, 2025). ValueAddVC also tracks 2 funds managed by OrbiMed Advisors.

Strategy

Stages

SeedSeries AGrowthLate Stage

Sectors

BiopharmaceuticalsMedical DevicesDigital HealthDiagnosticsHealthcare Services

Geographies

USANew York, New York, USA

Check size

$5M-$100M

Recent changes

Sep 5, 2026Sep 5, 2026Stages updated: Seed, Series A, Growth, Late Stage orbimed.com
Sep 5, 2026Sep 5, 2026Sectors updated: Biopharmaceuticals, Medical Devices, Digital Health, Diagnostics, Healthcare Services orbimed.com
Nov 5, 2025Nov 5, 2025Invested in Braveheart Bio (Series A, $185M) PR Newswire
Jun 1, 1998Jun 1, 1998New fund: OrbiMed Advisors Fund II SEC EDGAR Form D
Jan 1, 1993Jan 1, 1993New fund: OrbiMed Partners SEC EDGAR Form D

Funds

Fund	Vintage	Size	Strategy	Source
OrbiMed Advisors Fund II	1998	—	Flagship	As of Jul 10, 2026SEC EDGAR Form D
OrbiMed Partners	1993	—	Flagship	As of Jul 14, 2017SEC EDGAR Form D

Portfolio

7 total

Iambic Therapeutics World Labs ADARx Braveheart Bio Scribe Therapeutics Triveni Bio Biobeat

Recent Investment Activity

Track record: led 1 and participated in 1 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series B

Date	Company	Event	Role	Amount	Valuation	Investors	Source
Dec 30, 2025	Biobeat	Series B	Led	$50M	—	OrbiMed AdvisorsLeadElevage Medical TechnologiesLeadAlly Bridge Group	Refresh Miami
Nov 5, 2025	Braveheart Bio	Series A	Participated	$185M	—	Andreessen HorowitzForbion Capital PartnersOrbiMed AdvisorsEnavate Sciences (Patient Square Capital)Frazier Life Sciences	PR Newswire

Sector / Stage Activity

By sector (portfolio)

Biotech

5 · 71%

Medtech / cuff-less blood pressure monitoring

1 · 14%

By stage (tracked rounds)

Series B

1 · 50%

Series A

1 · 50%

Co-Investors

Andreessen Horowitz · 3 shared Ascenta Capital · 3 shared Fidelity Investments · 2 shared AMD Ventures · 1 shared Ashton Kutcher · 1 shared Atlas Venture · 1 shared Autodesk · 1 shared Bain Capital Life Sciences · 1 shared Enavate Sciences (Patient Square Capital) · 1 shared Forbion Capital Partners · 1 shared SR One Capital Management · 1 shared Viking Global Investors · 1 shared

Similar Firms

overlapping sector, stage or region

Initialized Capital Pear VC Blackbird Ventures .406 Ventures New Leaf Venture Partners Frist Cressey Ventures Palm Beach Capital New Stack Ventures

Latest Pulse

Jul 7, 2026FORE Biotherapeutics Raises $67.4M to Push BRAF Cancer DrugFORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension, bringing its total Series D-2 to $110 million, to fund late-stage development of plixorafenib toward a targeted 2027 FDA submission for BRAF-mutated tumors.→

OrbiMed Advisors FAQ

What companies has OrbiMed Advisors invested in?

OrbiMed Advisors' portfolio includes Iambic Therapeutics, World Labs, ADARx, Braveheart Bio, Scribe Therapeutics, Triveni Bio, and 1 more tracked companies.

Who does OrbiMed Advisors co-invest with most?

In the rounds Value Add tracks, OrbiMed Advisors most often invests alongside Andreessen Horowitz (3 shared deals), Ascenta Capital (3 shared deals), Fidelity Investments (2 shared deals), AMD Ventures (1 shared deal), Ashton Kutcher (1 shared deal).

Sources & methodologyshow

Where these figures come from

PR Newswireprimary source1 fact
SEC EDGAR Form Dprimary source1 fact
SEC EDGAR Form Dprimary source1 fact
Refresh Miamimajor outlet1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction